Alkem Laboratories
| Public company | |
| Traded as |
BSE: 539523 NSE: ALKEM |
| Industry | Pharmaceuticals |
| Founded | 1973 |
| Founder | Samprada Singh |
| Headquarters | Mumbai, Maharashtra, India |
Key people | Samprada Singh, Dhananjay Kumar Singh |
| Products | Pharmaceuticals, generic drugs |
| Revenue |
 ₹130 billion (US$1.9 billion) (2014-15)[1] |
|
₹31.82 billion (US$470 million) (2014–15) | |
|
₹11.44 billion (US$170 million) (2014–15) | |
| Total assets |
₹41.75 billion (US$620 million) (2014–15) |
| Total equity |
₹13.5 billion (US$200 million) (2014–15) |
| Owner | Samprada Singh |
| Website |
www |
Alkem Laboratories is a multinational pharmaceutical company headquartered in Mumbai, Maharashtra that manufactures and sells pharmaceutical generics, formulations and active pharmaceutical ingredients (APIs) primarily in India and also in United States, Australia, UK. Alkem has been among the top ten pharmaceutical companies in India for the past 12 years.It is currently the 5th largest and the 3rd fastest growing pharmaceutical company in India.Alkem produces branded generics, generic drugs, active pharmaceutical ingredient and nutraceuticals which are market in India and 55 countries internationally. With a wide ranging presence across acute and chronic therapeutic segments with substantial brand share in the Anti-infective, Gastro-intestinal, Pain Management, Vitamins / Minerals / Nutritions, Central Nervous System, Anti-diabetic, Anti-osteoporosis, Anti-malarial, Cardiovascular, Immunosuppressants, and Nutraceutical segments.
Company
Alkem Laboratories Limited was established by Samprada Singh in 1973 in Mumbai. In 1978 Alkem established its first manufacturing plant in Taloja. In 1992 the company was having other manufacturing plant in Mundra which was later converted to API in 2005. Alkem set up its research and development facility for ANDA development at Taloja in 2003. In 2006 anti-infective drug Taxim of Alkem became the first anti-infective drug in the Indian pharmaceutical industry to cross 1,000 million in terms of domestic sales in India. In 2014 Clavam other drug from Alkem crossed 2,000 millions mark in terms of domestic sales in India. In 2007 the company filed its first ANDA for drug Amlodipine which was approved in 2009. Alkem has developed a portfolio of 705 branded generic drugs, with 13 of the brands featured among the top 300 brands in India for the fiscal year 2015 and a portfolio of 705 brands in India in the six months ended September 30, 2015. Alkem have 16 manufacturing facilities, 14 in India and 2 in US. 5 of the facilities are US FDA, TGA, UK MHRA approved.
Acquisitions
Alkem has 16 manufacturing facilities: 14 in India and 2 in the US. These 2 facilities in the US were acquired in 2012 and 2013 respectively. In 2014 acquired the "Clindac-A" brand in India from Galderma S.A. In 2015 again Alkem acquired a formulation manufacturing facility in the US.
Governance and administration
Samprada Singh is the founder and chairman emeritus of the company, he lead and shaped Alkem what it is today, he is alumnus of Patna University and has a BCom degree from then Gaya College of Engineering.He is 49th richest person in India and a billionaire.[2] His brother, Basudeo Narayan Singh,[3] was also the co-founder of the company.
| Position | Name |
|---|---|
| Founder Chairman Emeritus | Mr. Samprada Singh |
| Executive Chairman | Mr.Basudeo Narayan Singh |
| Joint Managing Director | Mr.Dhananjay Kumar Singh |
| Joint Managing Director | Mr.Sandeep Singh |
| Executive Director | Mr.Mritunjay Kumar Singh |
| Independent Director | Mr.M. C. Shah |
| Independent Director | Mr.A.K. Purwar |
| Independent Director | Mr.A. M. Prasad |
| Independent Director | Mr.R. L. Shenoy |
| Independent Director | Ms.Sangeeta Singh |
| Independent Director | Ms.Sudha Ravi |
References
- ↑ "Alkem Laboratories Ltd. profit and loss (P&L), financial statement, accounts". rediff.com.
- ↑ "Samprada Singh & family". Forbes.
- ↑ "Basudeo Singh". Bloomberg.
- ↑ "Board of Directors". Alkem.